SCHEMBL250283

SCHEMBL250283

NC(=O)CCc1ccccc1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.46
MTNR1A P48039 1/20 0.43
MPO P05164 2/20 0.41
EGFR P00533 1/20 0.40
SRC P12931 1/20 0.40
CAPN1 P07384 1/20 0.40
KDM4E B2RXH2 3/20 0.39
NR4A2 P43354 1/20 0.38
HDAC3 O15379 2/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC2 Q92769 2/20 0.38
NCOR2 Q9Y618 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11232270 0.98 FDPS (0.44) FDPSMTNR1AMPOEGFRSRC
SCHEMBL3790529 0.90 FDPS (0.44) FDPSMTNR1AMPOKDM4EHDAC3
Hydrochloric Acid SCHEMBL10784054 0.88 FDPS (0.43) FDPSMTNR1AMPOKDM4EHDAC3
SCHEMBL9321175 0.87 MTNR1A (0.47) MTNR1AMPOEGFRSRCCAPN1
SCHEMBL89295 0.83 KEAP1 (0.54) FDPSNR4A2HDAC3HDAC1HDAC2
SCHEMBL14966254 0.82 FDPS (0.39) FDPSMTNR1AKDM4EHDAC3HDAC1
SCHEMBL414288 0.82 IAPP (0.55) FDPSKDM4EHDAC3HDAC1HDAC2
Hydrochloric Acid SCHEMBL9297129 0.80 IAPP (0.53) FDPSKDM4EHDAC3HDAC1HDAC2
SCHEMBL4764282 0.80 HDAC3 (0.47) FDPSKDM4EHDAC3HDAC1HDAC2
SCHEMBL860002 0.79 TAAR1 (0.57) MTNR1AMPOKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1613 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11633494-B2 Compounds and compositions for immunotherapy BIRDIE BIOPHARMACEUTICALS, INC. (KY) 2023-04-25 US claimed
US-11633495-B2 Compounds and compositions for immunotherapy BIRDIE BIOPHARMACEUTICALS, INC. (KY) 2023-04-25 US claimed
CN-115181164-A Derivatives of amatoxins and their coupling to cell binding molecules 杭州多禧生物科技有限公司 2022-10-14 CN claimed
CN-115124573-A Novel cytotoxic molecules for use in cell binding molecule-drug conjugates 杭州多禧生物科技有限公司 2022-09-30 CN claimed
EP-4056594-A1 COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY Birdie Biopharmaceuticals Inc. (KY) 2022-09-14 EP claimed
CN-109689107-B Derivatives of amatoxins and their coupling to cell binding molecules 杭州多禧生物科技有限公司 2022-08-16 CN claimed
US-20220047711-A1 PHOTOCROSSLINKING PEPTIDES FOR SITE SPECIFIC CONJUGATION TO FC-CONTAINING PROTEINS GENENTECH, INC. (US) 2022-02-17 US claimed
EP-3894427-A1 PHOTOCROSSLINKING PEPTIDES FOR SITE SPECIFIC CONJUGATION TO FC-CONTAINING PROTEINS Genentech, Inc. (US) 2021-10-20 EP claimed
CN-113227119-A Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins 基因泰克公司 2021-08-06 CN claimed
US-10836796-B2 Derivatives of amanita toxins and their conjugation to a cell binding molecule HANGZHOU DAC BIOTECH CO., LTD. (CN) 2020-11-17 US claimed
US-20200079820-A1 DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE HANGZHOU DAC BIOTECH CO., LTD. (CN) 2020-03-12 US claimed
US-20190269789-A1 COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY SHANGHAI BIRDIE BIOTECH, INC. (CN) 2019-09-05 US claimed
US-20190269790-A1 COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY SHANGHAI BIRDIE BIOTECH, INC. (CN) 2019-09-05 US claimed
US-10328158-B2 Compounds and compositions for immunotherapy BIRDIE BIOPHARMACEUTICALS, INC. (KY) 2019-06-25 US claimed
EP-3041846-B1 NOVEL CYTOTOXIC AGENTS FOR CONJUGATION OF DRUGS TO CELL BINDING MOLECULE HANGZHOU DAC BIOTECH CO LTD (CN) 2018-11-07 EP claimed
US-9988408-B2 Cytotoxic agents for conjugation to a cell binding molecule HANGZHOU DAC BIOTECH CO., LTD. (CN) 2018-06-05 US claimed
WO-2017046658-A1 DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE HANGZHOU DAC BIOTECH CO, LTD (CN) 2017-03-23 WO claimed
US-20160207949-A1 NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE HANGZHOU DAC BIOTECH CO., LTD (CN) 2016-07-21 US claimed
EP-3041846-A1 NOVEL CYTOTOXIC AGENTS FOR CONJUGATION OF DRUGS TO CELL BINDING MOLECULE Hangzhou Dac Biotech Co., Ltd (CN) 2016-07-13 EP claimed
WO-2015028850-A1 NOVEL CYTOTOXIC AGENTS FOR CONJUGATION OF DRUGS TO CELL BINDING MOLECULE HANGZHOU DAC BIOTECH CO., LTD (CN) 2015-03-05 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190269790-A1 COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY CD47, CD274, TP53 FDPS 926/4885MTNR1A 3481/4885MPO 597/4885
US-20200079820-A1 DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE ANTXR2, ANXA5, C3AR1 FDPS 4044/4885MTNR1A 1179/4885MPO 1131/4885
US-11633494-B2 Compounds and compositions for immunotherapy CD47, CD274, TP53 FDPS 926/4885MTNR1A 3481/4885MPO 597/4885
US-20160207949-A1 NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE PDCD5, CD4, PDCD6 FDPS 4583/4885MTNR1A 2027/4885MPO 3281/4885
US-10836796-B2 Derivatives of amanita toxins and their conjugation to a cell binding molecule ANTXR2, ANXA5, C3AR1 FDPS 3939/4885MTNR1A 1152/4885MPO 1165/4885
US-11633495-B2 Compounds and compositions for immunotherapy CD47, CD274, TP53 FDPS 926/4885MTNR1A 3481/4885MPO 597/4885
US-20190269789-A1 COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY CD47, CD274, TP53 FDPS 926/4885MTNR1A 3481/4885MPO 597/4885
US-10328158-B2 Compounds and compositions for immunotherapy CD47, CD274, TP53 FDPS 926/4885MTNR1A 3481/4885MPO 597/4885
US-20220047711-A1 PHOTOCROSSLINKING PEPTIDES FOR SITE SPECIFIC CONJUGATION TO FC-CONTAINING PROTEINS FCGR2A, FCGR3B, DNPEP FDPS 1240/4885MTNR1A 1753/4885MPO 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.